Compare QQQX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QQQX | SPRY |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 946.0M |
| IPO Year | N/A | N/A |
| Metric | QQQX | SPRY |
|---|---|---|
| Price | $28.04 | $10.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.25 |
| AVG Volume (30 Days) | 127.6K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $124.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5459.66 |
| 52 Week Low | $20.27 | $6.66 |
| 52 Week High | $25.99 | $18.90 |
| Indicator | QQQX | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 58.86 |
| Support Level | $28.18 | $9.77 |
| Resistance Level | $28.62 | $11.45 |
| Average True Range (ATR) | 0.34 | 0.66 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 64.80 | 72.24 |
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.